Skip to Main Content

Paper Details

Synergistic anti-tumor efficacy of mutant isocitrate dehydrogenase 1 inhibitor SYC-435 with standard therapy in patient-derived xenograft mouse models of glioma.
Transl Oncol
6
2022
1-hydroxypyridin-2-one, BCL9, CTC1, H3K4, H3K9, IC-BT142AOA, IC-V0914AOA, IDH1, IDH1 mutant, IDH1 mutant gliomas, Isocitrate, Isocitrate dehydrogenase 1, MYO1F, R132C, R132H, SYC-435, Temozolomide, WHO grade II/III, astrocytoma, eukaryotic initiation factor 2, genes, glioblastoma, glioma, isocitrate, mouse, mutant IDH1, mutant isocitrate dehydrogenase 1, oligodendroglioma, orthotopic glioma xenograft model, patient, patients, protein kinase A, recurrent anaplastic oligoastrocytoma, sirtuin, tumor, tumors
Author NameAffiliation
Lin QiPreclinical Neuro-Oncology Research Program, Baylor College of Medicine, USA Texas Children's Cancer Center, Texas Children's Hospital, Simpson Querrey Biomedical Research Center, Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine
Frank K BraunPreclinical Neuro-Oncology Research Program, Baylor College of Medicine, USA Texas Children's Cancer Center, Texas Children's Hospital
Huiyuan ZhangPreclinical Neuro-Oncology Research Program, Baylor College of Medicine, USA Texas Children's Cancer Center, Texas Children's Hospital
Holly LindsayPreclinical Neuro-Oncology Research Program, Baylor College of Medicine, USA Texas Children's Cancer Center, Texas Children's Hospital
Holly LindsayPreclinical Neuro-Oncology Research Program, Baylor College of Medicine, USA Texas Children's Cancer Center, Texas Children's Hospital
Sibo ZhaoPreclinical Neuro-Oncology Research Program, Baylor College of Medicine, USA Texas Children's Cancer Center, Texas Children's Hospital
Patricia BaxterTexas Children's Cancer Center, Texas Children's Hospital
Donald W ParsonsTexas Children's Cancer Center, Texas Children's Hospital
Donald W ParsonsTexas Children's Cancer Center, Texas Children's Hospital
Murali ChintagumpalaTexas Children's Cancer Center, Texas Children's Hospital
Xiao-Nan LiPreclinical Neuro-Oncology Research Program, Baylor College of Medicine, USA Texas Children's Cancer Center, Texas Children's Hospital, Simpson Querrey Biomedical Research Center, Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine
  • 1 - 11

Datasets

Release 1.2